The role of cytokines in unstable angina

L M Biasucci1, G Liuzzo, C Colizzi

  • 1Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy.

Insights

Inflammation, driven by cytokines like IL-6, is key in unstable angina. Targeting this inflammation may offer new therapeutic strategies for acute coronary syndromes.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Biochemistry

Background:

  • Inflammation is increasingly recognized in unstable angina pathogenesis.
  • Acute phase proteins like C-reactive protein (CRP) and fibrinogen indicate inflammation's role.
  • Pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6), likely mediate this inflammatory process.

Purpose of the Study:

  • To explore the involvement of pro-inflammatory cytokines in unstable angina.
  • To understand the mechanisms by which cytokines contribute to acute coronary syndromes.
  • To evaluate the potential of anti-inflammatory therapy for unstable angina.

Main Methods:

  • Review of existing evidence on inflammation and acute phase proteins in unstable angina.
  • Analysis of studies reporting cytokine levels in patients with acute coronary syndromes.
  • Discussion of potential cytokine-mediated pathways including endothelial dysfunction, plaque instability, and immune cell activation.

Main Results:

  • Elevated levels of IL-1 and IL-6 are observed in patients with acute coronary syndromes.
  • Cytokines may promote coagulation, endothelial dysfunction, and plaque rupture.
  • Cytokines can activate immune cells like neutrophils and mast cells.

Conclusions:

  • Cytokines play multifaceted roles in the pathophysiology of unstable angina.
  • The precise trigger and mechanisms of cytokine activation in this condition remain unclear.
  • Targeted anti-inflammatory therapies represent a promising future treatment avenue for unstable angina.

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Angina I: Introduction01:30

Angina I: Introduction

Definition and Symptoms: Angina (angina pectoris) is chest pain or discomfort caused by myocardial ischemia, which occurs when the heart muscle receives insufficient oxygen-rich blood. It typically manifests as pressing, squeezing, or crushing sensations in the chest and may radiate to the shoulders, arms, neck, jaw, or back.Primary Cause: In a healthy state, the coronary arteries can dilate (widen) to increase blood flow and meet the increased oxygen demand during physical activity or...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...